These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. "Getting the dose right": facts, a blueprint, and encouragements. Peck CC; Cross JT Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068 [No Abstract] [Full Text] [Related]
23. Prospects for reform of the IND/NDA processes: part II. Romansky MA J Clin Psychopharmacol; 1982 Dec; 2(6):424-6. PubMed ID: 7174868 [No Abstract] [Full Text] [Related]
24. FDA perspective on clinical trial design for femoropopliteal stent correction of peripheral vascular insufficiency cardiovascular devices. Goode J; Sapirstein W; Zuckerman B Catheter Cardiovasc Interv; 2007 May; 69(6):920-1. PubMed ID: 17455345 [No Abstract] [Full Text] [Related]
26. Improving protection for research subjects. Steinbrook R N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426 [No Abstract] [Full Text] [Related]
27. Clinical research: outlook from industry. Echols R Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942 [No Abstract] [Full Text] [Related]
28. End points in irritable bowel syndrome. Mangel AW; Fehnel SE Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345 [No Abstract] [Full Text] [Related]
29. The Dunlop phenomena: a lesson in risk management from an unlikely source. Williams D Med Device Technol; 2003 Apr; 14(3):9-10. PubMed ID: 12789692 [TBL] [Abstract][Full Text] [Related]
30. Regulated clinical research: the study design. Asher HR; Walsh SM Med Instrum; 1986; 20(4):220-3. PubMed ID: 3762453 [No Abstract] [Full Text] [Related]
31. Case study: agency says institutional review board (IRB) failed to warn subjects of significant problems. Maloney DM Hum Res Rep; 2006 Mar; 21(3):6-7. PubMed ID: 16789303 [No Abstract] [Full Text] [Related]
32. Design and analysis issues for economic analysis alongside clinical trials. Marshall DA; Hux M Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012 [TBL] [Abstract][Full Text] [Related]
33. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration. James JS AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627 [TBL] [Abstract][Full Text] [Related]
34. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Huang SM; Temple R; Throckmorton DC; Lesko LJ Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955 [TBL] [Abstract][Full Text] [Related]
35. Ethics and evidence in clinical trials. Goodman SN Clin Trials; 2005; 2(3):195-6. PubMed ID: 16279142 [No Abstract] [Full Text] [Related]
36. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop. Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207 [TBL] [Abstract][Full Text] [Related]
37. Doing more with less. Reengineering a rehab hospital for cost-effectiveness entails a new way of thinking. Kreitner C; Hartz A; Pflum R Rehab Manag; 1997; 10(6):62, 65-7, 116. PubMed ID: 10174306 [No Abstract] [Full Text] [Related]
39. Prospects for reform of the IND/NDA processes: Part I. Romansky MA J Clin Psychopharmacol; 1982 Oct; 2(5):358-61. PubMed ID: 6752215 [No Abstract] [Full Text] [Related]